Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

391 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma.
Wu Q, Zhen Y, Shi L, Vu P, Greninger P, Adil R, Merritt J, Egan R, Wu MJ, Yin X, Ferrone CR, Deshpande V, Baiev I, Pinto CJ, McLoughlin DE, Walmsley CS, Stone JR, Gordan JD, Zhu AX, Juric D, Goyal L, Benes CH, Bardeesy N. Wu Q, et al. Among authors: zhu ax. Cancer Discov. 2022 May 2;12(5):1378-1395. doi: 10.1158/2159-8290.CD-21-1168. Cancer Discov. 2022. PMID: 35420673 Free PMC article.
Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.
Deshpande V, Nduaguba A, Zimmerman SM, Kehoe SM, Macconaill LE, Lauwers GY, Ferrone C, Bardeesy N, Zhu AX, Hezel AF. Deshpande V, et al. Among authors: zhu ax. BMC Cancer. 2011 Feb 8;11:60. doi: 10.1186/1471-2407-11-60. BMC Cancer. 2011. PMID: 21303542 Free PMC article.
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, Schenkein DP, Hezel AF, Ancukiewicz M, Liebman HM, Kwak EL, Clark JW, Ryan DP, Deshpande V, Dias-Santagata D, Ellisen LW, Zhu AX, Iafrate AJ. Borger DR, et al. Among authors: zhu ax. Oncologist. 2012;17(1):72-9. doi: 10.1634/theoncologist.2011-0386. Epub 2011 Dec 16. Oncologist. 2012. PMID: 22180306 Free PMC article.
Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma.
O'Dell MR, Huang JL, Whitney-Miller CL, Deshpande V, Rothberg P, Grose V, Rossi RM, Zhu AX, Land H, Bardeesy N, Hezel AF. O'Dell MR, et al. Among authors: zhu ax. Cancer Res. 2012 Mar 15;72(6):1557-67. doi: 10.1158/0008-5472.CAN-11-3596. Epub 2012 Jan 20. Cancer Res. 2012. PMID: 22266220 Free PMC article.
Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy.
Arvold ND, Willett CG, Fernandez-del Castillo C, Ryan DP, Ferrone CR, Clark JW, Blaszkowsky LS, Deshpande V, Niemierko A, Allen JN, Kwak EL, Wadlow RC, Zhu AX, Warshaw AL, Hong TS. Arvold ND, et al. Among authors: zhu ax. Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):e337-43. doi: 10.1016/j.ijrobp.2011.12.068. Epub 2012 Mar 11. Int J Radiat Oncol Biol Phys. 2012. PMID: 22414286
Targeting the HGF/c-MET pathway in hepatocellular carcinoma.
Goyal L, Muzumdar MD, Zhu AX. Goyal L, et al. Among authors: zhu ax. Clin Cancer Res. 2013 May 1;19(9):2310-8. doi: 10.1158/1078-0432.CCR-12-2791. Epub 2013 Feb 6. Clin Cancer Res. 2013. PMID: 23388504 Free PMC article. Review.
FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.
Faris JE, Blaszkowsky LS, McDermott S, Guimaraes AR, Szymonifka J, Huynh MA, Ferrone CR, Wargo JA, Allen JN, Dias LE, Kwak EL, Lillemoe KD, Thayer SP, Murphy JE, Zhu AX, Sahani DV, Wo JY, Clark JW, Fernandez-del Castillo C, Ryan DP, Hong TS. Faris JE, et al. Among authors: zhu ax. Oncologist. 2013;18(5):543-8. doi: 10.1634/theoncologist.2012-0435. Epub 2013 May 8. Oncologist. 2013. PMID: 23657686 Free PMC article.
391 results